Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $34.7000 (-2.47%) ($34.7000 - $34.7000) on Mon. Nov. 8, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.26% (three month average) | RSI | 67 | Latest Price | $34.7000(-2.47%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 1.2% a day on average for past five trading days. | Weekly Trend | TGTX advances 3.9% a week on average for past two weeks. | Market Behavior | Normal for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(70%) ARKG(65%) IBB(62%) ARKK(61%) IWO(60%) | Factors Impacting TGTX price | TGTX will decline at least -1.63% in a week (0% probabilities). VIXM(-48%) VXX(-39%) UUP(-19%) UNG(-7%) TLT(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.63% (StdDev 3.26%) | Hourly BBV | 0.1 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $34.13(1.67%) | 10 Day Moving Average | $33(5.15%) | 20 Day Moving Average | $32.7(6.12%) | To recent high | -2.5% | To recent low | 60.1% | Market Cap | $4.395b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |